{"summary": "randomized, placebo-controlled phase IV trial was conducted in 200 adult patients with self-diagnosed colds of 48 h\u2019 duration. patients were to self-administer 0.12 % I-C or placebo spray four times daily for four to ten days. common respiratory viruses were quantified by RT-PCR during pretreatment. I-C: 90.2 % reduction in viral load; placebo: 72.0 %) treatments were well tolerated with no differences in adverse event rates. primary endpoint did not demonstrate a statistically significant difference."}